Nautilus Biotechnology (NASDAQ:NAUT) said it is shifting a significant share of its research and development resources toward proteoform applications, citing customer interest and a delay in its Broadscale broad-proteome program.
Chief Executive Officer Sujal Patel said the company’s platform has developed faster for proteoform analysis than it initially anticipated
Proteoform assays are designed to measure specific molecular states of proteins, including isoform composition and modification patterns. Nautilus said customer feedback has indicated that this level of resolution is a differentiated and commercially relevant capability. “We’re putting the bulk of our resources behind Proteoforms because that’s where we can deliver unique value today,” Patel said. The company will retain a focused Broadscale team, but said the reprioritization will slow that program’s development pace.
Broadscale Timeline Moves Beyond 2027 Nautilus said second-quarter testing showed that changes to its assay configuration did not sufficiently improve probe-candidate performance to support general availability of Broadscale in 2027 at the company’s target specifications. The company did not provide a revised availability date. Chief Scientist Parag Mallick said remaining work on Broadscale centers on increasing diversity in the probe library through affinity maturation, improving the machine-learning layer with additional platform data, and stabilizing the assay architecture to detect true-positive binding events more reliably. “The underlying science is sound,” Mallick said, while noting that some development efforts carry lead times of several quarters.